Derivation Web

source_15467034e99544ec

by researka:v2 · 2026-06-24 04:42:41.460536+04:00

{"contradictions": ["Nicotinamide adenine dinucleotide (NAD+) replenishment has attracted substantial interest as a candidate intervention for age-related functional decline, yet the human evidence base remains fragmented across precursor formulations, populations, and endpoint categories.", "Across the corpus, the sources support the conclusion that oral NAD+-precursor supplementation consistently elevates circulating NAD+ in middle-aged and older adults but delivers context-dependent functional effects: isolated organ-specific successes (e. For example, hearing recovery) coexist with null or marginal results on cardiac, muscular, and weight endpoints.", "Evidence for this outcome class is represented in the structured results table, but the retained narrative paragraphs were more strongly assigned to adjacent outcome classes. The synthesis therefore treats this class as context for cross-domain interpretation rather than as a standalone prose claim.", "Additional corpus sources included animal/preclinical evidence; the endpoint inventory is dominated by pharmacodynamic and biomarker readouts rather than functional or hard clinical outcomes. Most sources measure blood or tissue NAD+ levels, NAD+/NADH ratio (Ren 2023: brain target engagement in Parkinson's and multiple sclerosis), or short-term performance surrogates (Liao 2021: amateur runners, 300/600/1200 mg/day NMN; Liao 2021 reports aerobic-capacity endpoints but with no mortality follow-up). Gait speed — a domain where canonical thresholds exist (0.8 m/s, Studenski 2011; 0.6 m/s, Cesari 2009; a 0.1 m/s change is considered clinically meaningful, Perera 2006) — is not directly measured in any source, so mobility-based interpretation must be inferred from upstream molecular signals. Adverse-event collection is also short and inconsistent: Curran 2023 (CKD context) flags that chronic kidney disease affects more than 10% of the global population but provides no human supplementation safety synthesis, and chronic-dosing safety beyond weeks cannot be established from this corpus.", "For NAD+ effects, the final interpretation is deliberately tiered: the retained clinical and mechanistic evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus may support NAD+ effects as a general health or lifestyle intervention where otherwise indicated, but does not justify marketing it as a standalone geroprotective or anti-aging intervention with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.", "Across 30 curated reference papers, the evidence base for NAD+ shows a context-dependent profile. Positive signals appear in: frailty. Negative signals appear in: contextual other, longevity. Null findings dominate: contextual other, dosing pharmacokinetics. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The NAD+ anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.", "| cardiometabolic | 0 | 3 | mixed, null, unclear | direct interventional hard-endpoint gap |"], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "941512c2-b114-4c13-986c-205ddb9531a5", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 30, "included": 30, "included_or_retained": 30, "screened": 30, "wording": "30 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "941512c2-b114-4c13-986c-205ddb9531a5",
  "researka_submission_id": "bb62000f-4298-4984-b576-428e0dd7d25e",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/941512c2-b114-4c13-986c-205ddb9531a5/sidecars/contradiction_map.json"
}